Kratos Defense stock (KTOS) jumps again on Valkyrie drone deal, Trump budget push and fresh target hikes

Kratos Defense stock (KTOS) jumps again on Valkyrie drone deal, Trump budget push and fresh target hikes

New York, Jan 10, 2026, 21:10 EST — Market closed.

Shares of Kratos Defense & Security Solutions (KTOS) ended Friday at $113.70, gaining 9.3% after fluctuating between $104.65 and $115.45. The stock has surged roughly 43% since closing on Jan. 2, with about 6 million shares changing hands Friday.

The recent surge came after a defense-sector rally sparked by President Donald Trump’s proposal to boost the 2027 U.S. military budget to $1.5 trillion — well above the $901 billion set for 2026 — and his suggestion to cap dividends and buybacks unless contractors accelerate production. Lockheed Martin climbed 4.3%, Northrop Grumman added 2.4%, and Kratos soared 13.8% on Thursday.

Kratos positioned itself as aligned with that trend on Thursday, backing policies that favor reinvestment instead of shareholder returns. The company confirmed it neither does stock buybacks nor pays dividends. CEO Eric DeMarco emphasized the firm’s goal is “not financial engineering.” Kratos Defense

Kratos also announced that Northrop has been chosen to quickly develop the Marine Corps’ first Collaborative Combat Aircraft (CCA). These are pilotless “wingmen” meant to fly alongside crewed jets, built around Kratos’ XQ-58A Valkyrie airframe. Steve Fendley, head of Kratos’ unmanned systems division, said the goal is to produce a “high capability” CCA “at a price point that enables” mass deployment. Kratos Defense

Breaking Defense reported the award comes as an Other Transaction Agreement, or OTA—a Pentagon contract format designed to speed things up compared to standard procurement deals. The OTA is initially valued at $231.5 million with a 24-month performance window.

Analysts jumped on the news. B. Riley bumped up its price target on Kratos to $128 from $105, maintaining its buy rating. The boost reflects potential gains tied to the administration’s hint at a 50% increase in the initial FY2027 defense budget to $1.5 trillion, according to The Fly.

Truist raised its price target to $135 from $125, maintaining a buy rating. The firm sees the aerospace and defense sector as generally promising for 2026 but pointed out that smaller defense-tech stocks carry stretched valuations.

The situation isn’t one-sided. The budget still needs Congressional approval, and Kratos’ Marine Corps program remains in development. The company hasn’t disclosed any expected revenue from a Northrop-led contract. According to a Form 4 filed on Jan. 9, David M. Carter, president of Kratos’ DRSS division, sold 12,123 shares between Jan. 7-8, following a 10b5-1 plan established last June.

U.S. markets remain closed until Monday, putting the spotlight on any updates about the Marine Corps initiative and fresh clues on Pentagon spending tied to Trump’s plan. Kratos is set to release its next earnings report on Feb. 25, according to Zacks.

Khadija Saeed

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors. Follow Khadija Saeed on Google News.

AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 STRONG BUY

AerCap

NYSE: AER 95 / 100
#2 BUY

Constellation Energy

NASDAQ: CEG 94 / 100
#3 BUY ON PULLBACK

Cheniere Energy

NYSE: LNG 92 / 100
#4 BUY

Walt Disney

NYSE: DIS 90 / 100
#5 ACCUMULATE

AIG

NYSE: AIG 88 / 100
View full portfolio
Editorial model selection. Not personalised advice.
Eos Energy (EOSE) stock jumps 9% — what investors watch before Monday’s open
Previous Story

Eos Energy (EOSE) stock jumps 9% — what investors watch before Monday’s open

TG Therapeutics stock slid nearly 7% Friday — what to watch next week for TGTX
Next Story

TG Therapeutics stock slid nearly 7% Friday — what to watch next week for TGTX